Paclitaxel （neoadjuvant）

PreclinicalSmall molecule

SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Paclitaxel （neoadjuvant） is one of 91 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Head and Neck Squamous Cell Carcinoma

NCT06575322

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT06576180·306 enrolled

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT06575322·302 enrolled

Breast Cancer1 trial

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

Unknown status·IInstitut Català d'Oncologia··NCT05912062·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Paclitaxel （neoadjuvant）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel （neoadjuvant） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel （neoadjuvant）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Paclitaxel （neoadjuvant）

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News